Posted by Michael Wonder on 20 Jul 2016
Allergan and Adamas announce new expanded indication for Namzaric (memantine and donepezil hydrochloride) extended release for the treatment of moderate to severe Alzheimer's disease
19 July 2016 - Patients currently treated with donepezil hydrochloride 10 mg can now start therapy directly with once daily Namzaric.
Allergan and Adamas Pharmaceuticals today announced that the U.S. FDA has approved a new, expanded label for Namzaric (memantine and donepezil hydrochloride) extended-release, a once-daily, fixed-dose combination of memantine hydrochloride (a NMDA receptor antagonist) and donepezil hydrochloride (an acetylcholinesterase inhibitor).
With the new indication, patients with moderate to severe Alzheimer's disease, who are currently stabilized on Aricept, donepezil hydrochloride (10 mg), can now start combination therapy directly with Namzaric. Approximately 75% of patients diagnosed with Alzheimer's disease are in the moderate to severe stage of the disease and yet only about one-third of these patients are treated with combination therapy.
